NCT02367781 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 483
- group Id
- BG001
- value
- 240
- group Id
- BG002
- value
- 723
- units
- Participants
- groups
- description
- Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
- id
- BG000
- title
- Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)
- description
- Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
- id
- BG001
- title
- Arm B (Nab-Paclitaxel+Carboplatin)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.5
- value
- 63.8
- group Id
- BG001
- spread
- 8.9
- value
- 64.4
- group Id
- BG002
- spread
- 9.3
- value
- 64.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 206
- group Id
- BG001
- value
- 102
- group Id
- BG002
- value
- 308
- title
- Female
- measurements
- group Id
- BG000
- value
- 277
- group Id
- BG001
- value
- 138
- group Id
- BG002
- value
- 415
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 37
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 426
- group Id
- BG001
- value
- 213
- group Id
- BG002
- value
- 639
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 47
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 17
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 26
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 428
- group Id
- BG001
- value
- 222
- group Id
- BG002
- value
- 650
- title
- White
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 28
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 483
- group Id
- BG001
- value
- 240
- group Id
- BG002
- value
- 723
- units
- Participants
- groups
- description
- Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
- id
- BG000
- title
- Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)
- description
- Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.
- id
- BG001
- title
- Arm B (Nab-Paclitaxel+Carboplatin)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.5
- value
- 63.8
- group Id
- BG001
- spread
- 8.9
- value
- 64.4
- group Id
- BG002
- spread
- 9.3
- value
- 64.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 206
- group Id
- BG001
- value
- 102
- group Id
- BG002
- value
- 308
- title
- Female
- measurements
- group Id
- BG000
- value
- 277
- group Id
- BG001
- value
- 138
- group Id
- BG002
- value
- 415
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 37
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 426
- group Id
- BG001
- value
- 213
- group Id
- BG002
- value
- 639
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 32
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 47
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 17
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 26
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 428
- group Id
- BG001
- value
- 222
- group Id
- BG002
- value
- 650
- title
- White
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 28
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle